A single-blind, placebo-controlled, multicentre study evaluating continued long-term treatment with satavaptan (SR121463B) in patients with ascites due to liver cirrhosis who have previously been treated in studies LTS5634 or LTS5635.
Latest Information Update: 05 Oct 2021
At a glance
- Drugs Satavaptan (Primary)
- Indications Ascites; Liver cirrhosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms PASCCAL-1
- Sponsors Sanofi
- 13 Sep 2021 New trial record